NBRV - Nabriva Therapeutics AG - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

NBRV is currently covered by 1 analysts with an average price target of $-22. This is a potential upside of $-22.4 (-5600%) from yesterday's end of day stock price of $0.4.

Nabriva Therapeutics AG's activity chart (see below) currently has 0 price targets and 7 ratings on display. The stock rating distribution of NBRV is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 75% with an average time for these price targets to be met of 145.5 days.

Highest price target for NBRV is $7, Lowest price target is $1, average price target is $-22.

Most recent stock forecast was given by CARL BYRNES from NORTHLAND CAPITAL MARKETS on 06-Jan-2023. First documented stock forecast 07-Dec-2020.

Best performing analysts who are covering NBRV - Nabriva Therapeutics AG:

David Lebowitz Carl Byrnes

Currently out of the existing stock ratings of NBRV, 2 are a BUY (100%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

1

$0.6 (150.00%)

18

1 years 2 months 22 days ago

1/2 (50%)

$-0.3 (-23.08%)

207

Hold

50

$49.6 (12400.00%)

3 years 3 months 21 days ago

1/1 (100%)

$-44.5 (-47.09%)

84

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NBRV (Nabriva Therapeutics AG) average time for price targets to be met?

On average it took 145.5 days on average for the stock forecasts to be realized with a an average price target met ratio 75

Which analyst has the current highest performing score on NBRV (Nabriva Therapeutics AG) with a proven track record?

DAVID LEBOWITZ

Which analyst has the current lower performing score on NBRV (Nabriva Therapeutics AG) with a proven track record?

CARL BYRNES

Which analyst has the most public recommendations on NBRV (Nabriva Therapeutics AG)?

David Lebowitz works at CITI and has 10 price targets and 6 ratings on NBRV

Which analyst is the currently most bullish on NBRV (Nabriva Therapeutics AG)?

David Lebowitz with highest potential upside - $49.6

Which analyst is the currently most reserved on NBRV (Nabriva Therapeutics AG)?

Carl Byrnes with lowest potential downside - $0.6

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?